Moclobemide and clomipramine in endogenous depression
- 1 June 1989
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 79 (6) , 523-529
- https://doi.org/10.1111/j.1600-0447.1989.tb10298.x
Abstract
The purpose of this study was to compare moclobemide and clomipramine in endogenous depression according to the Newcastle II classification. Sixty-two patients were allocated to either 300 mg moclobemide or 150 mg clomipramine, both given in 3 daily doses. Improvements occurred over time but differences between treatments were never statistically significant. Dizziness, tremor and anticholinergic symptoms were significantly more frequent with clomipramine.Keywords
This publication has 11 references indexed in Scilit:
- Moclobemide and clomipramine in reactive depressionActa Psychiatrica Scandinavica, 1989
- A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illnessJournal of Affective Disorders, 1985
- Moclobemide and clomipramine in the treatment of depression.Acta Psychiatrica Scandinavica, 1984
- Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential Type A inhibition, in healthy volunteers and depressive patientsEuropean Journal of Clinical Pharmacology, 1983
- Neurochemical Effects in vitro and in vivo of the Antidepressant Ro 11-1163, a Specific and Short-Acting MAO-A InhibitorPublished by S. Karger AG ,1982
- Antidepressant Effect of Ro 11-1163, a New MAO InhibitorInternational Pharmacopsychiatry, 1982
- Correlation of Subjective Side Effects with Plasma Concentrations of NortriptylineBMJ, 1970
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959